PTO/SB/21 (08-00)

a plus sign (+) inside this box -> [+]

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TDAN			Application Number	09/876,252		
TRANSMITTAL			Filing Date	June 7, 2001	9	
FORM (to be used for all correspondence after initial filing)		First Named Inventor	Dominic P. Behan			
		Group Art Unit	1646			
		*	Examiner Name	N. Basi	ت ت	
Total Number of Pages in This Submission			Attorney Docket Number	12.US24.CON	8/	
		ENCL	OSURES (check all that apply)		] ]90	
Fee Transmittal Fo	orm		ment Papers Application)	After Allowance Commun Group		
Fee Attached		Drawin	g(s)	Appeal Communication to Appeals and Interference		
Amendment / Res	ponse	Licensi	ing-related Papers	Appeal Communication t		
After Final		Petition	1	Proprietary Information	Dife!)	
Affidavits/decl	aration(s)		n to Convert to a onal Application	☐ Status Letter		
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):		
Express Abandonment Request			al Disclaimer st for Refund	Form PTO/SB/08A (		
☐ Information Disclos	sure Statement	CD, Nu	ımber of CD(s)			
Certified Copy of Priority		Rema	rks			
Response to Missi Incomplete Applica						
Response to Missing Parts under 37 CFR 1.52 or 1.53						
	SIGNA	TURE OF A	APPLICANT, ATTORNEY, O	R AGENT		
Firm or Individual name  Gwilym J.O. Attwell, Registration No. 45,449						
Signature Gual Veet				:	4	
Date April 2, 2003						
		CE	RTIFICATE OF MAILING			
I hereby certify that this	s correspondence is	s being depos	sited with the United States Post	al Service as first class mail in a	an envelope	
addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:						
Typed or printed name Gwilym J.O. Attwell, Registr			tration No. 45,449			
Signature				Date Paril 2 200	2	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**PATENT** 

7 APR 0 9 2003 ECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

D. Behan et al.

: Art Unit: 1646

Serial No.:

09/876,252

: Examiner: N. Basi

Filed:

June 7, 2001

For:

NON-ENDOGENOUS,

CONSTITUTIVELY ACTIVATED HUMAN G PROTEIN-COUPLED

**RECEPTORS** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

DATE OF DEPOSIT: Hprild, 2003
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D. C. 2021

TYPED NAME: GWILYM J.O. ATTWELL

REGISTRATION NO: 45,449

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO/SB/08A submitted herewith. A copy of each of the listed references is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

More than three months have elapsed since the filing of the above-referenced application and a first (non-Final) Official Action has been received. No Final Action or Notice of Allowance has yet been received and it is presumed that none has yet been mailed. Accordingly, please charge the required fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1275.

Respectfully submitted,

Gwilym J.O. Attwell Registration No. 45,449 Attorney for Applicants

**Enclosures:** 

Form PTO/SB/08A Copy of (9) References

Dated: April 2,2003

Cozen O'Connor 1900 Market Street – 6<sup>th</sup> Floor Philadelphia, PA 19103

Tel: (215) 665-2000

APR 0 7 2003

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/876,252

Filing Date June 7, 2001

First Named Inventor Dominic P. Behan

Group Art Unit 1646

Examiner Name N. Basi

(use as many sheets as necessary)

Sheet 1 of 2

Substitute for form 1449A/PTO

Attorney Docket Number 7.US27.DIV

U.S. PATENT DOCUMENTS							
Examiner Cite No.1	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
	Number - Kind Code <sup>2</sup> (if known)	144.00.1000/	Cited Document	Passages or Relevant Figures Appear			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			44 11 2 (6) 3		
		US-					
	1	US-					

FOREIGN PATENT DOCUMENTS							
Examiner Cite No.1		Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
		WO 01/64836 A2	09/07/2001	Smithkline Beecham Corporation			
		WO 99/64436 A1	12/16/1999	Merck & Co., Inc.			
		WO 01/32710 A1	05/10/2001	Merck & Co., Inc			
		WO 02/057791 A2	07/25/2002	Lifespan Biosciences, Inc.			
		WO 01/38355 A2	05/31/2001	Zymogenetics, Inc.			
		WO 00/22131	04/20/2000	Arena Pharmaceuticals, Inc.			
			2,7				

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.
<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC	)			Complete if Known		
INIEO	DRAKTION	DIG	CLOSUBE	Application Number	09/876,252		F
INFORMATION DISCLOSURE				Filing Date	June 7, 2001		λ
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Dominic P. Behan	=====	¢
				Group Art Unit	1646	فظ	و
(use as many sheets as necessary)			necessary)	Examiner Name	N. Basi	<b>5</b>	,
Sheet	2	of	2	Attorney Docket Number	7.US27.DIV	8	7

,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	00			
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	K. KULJU MCKEE ET AL., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors," Genomics, 1997, Vol. 46, pages 426-434				
	A. FARWELL ET AL., Thyroid and Antithyroid Drugs," Goodman & Gilman's The Pharmacological Basis of Therapeutics, 1995, Chapter 56, pages 1383-1409				
	A. KURIU ET AL., "Proliferation of Human Myeloid Leukemia Cell Line Associated With the Tyrosine-Phosphorylation and Activation of the Proto-oncogene c-kit Product," <u>Blood</u> , December 1, 1991, Vol. 78, No. 11, pages 2834-2840				
		Cite No.   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  K. KULJU MCKEE ET AL., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors," Genomics, 1997, Vol. 46, pages 426-434  A. FARWELL ET AL., Thyroid and Antithyroid Drugs," Goodman & Gilman's The Pharmacological Basis of Therapeutics, 1995, Chapter 56, pages 1383-1409  A. KURIU ET AL., "Proliferation of Human Myeloid Leukemia Cell Line Associated With the Tyrosine-Phosphorylation and Activation of the Proto-oncogene c-kit Product," Blood, December 1, 1991, Vol. 78, No. 11.			

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.